Membranolytic peptide programs immunogenic cell death for cancer therapy.

Synthetic pH-responsive membranolytic peptide induces immunogenic cell death, boosting immune checkpoint therapy efficacy in tumors with 50% enhanced response.

• Why it matters: Overcoming tumor immune evasion remains a challenge in cancer therapy, and inducing immunogenic cell death can improve immune system activation against tumors.
• What they did: Researchers designed and implemented a synthetic acid-responsive peptide, aMP C16-CA50, to trigger a unique, time-lagged membranolytic cell death in tumor cells, promoting immune activation.
• The result: This approach enhanced antigen presentation and T cell activation, significantly improving antitumor immune responses and therapy outcomes, with systemic safety demonstrated in mice.